The proteasome is a multicatalytic proteinase complex responsible for the degradation of
most intracellular proteins, including proteins crucial to cell cycle regulation and …

Velcade (bortezomib), the first in a new class of investigational drugs known as proteasome
inhibitors, was approved for use in multiple myeloma in record-making time—only 4 months …

Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the
treatment of multiple myeloma (MM). Despite its demonstrated clinical success, some …

The ubiquitin-proteasome pathway is involved in intracellular protein turnover and plays an
essential function in many cellular processes, thus contributing to cellular homeostasis. The …

The proteasome inhibitor bortezomib (VELCADE™; formerly PS-341, LDP-341, MLN341) is
a novel dipeptide boronic acid. In cell culture and xenograft models, bortezomib showed …

The ubiquitin-proteasome pathway regulates many basic cellular processes and has been
proven to be a promising target for cancer therapy. Bortezomib is the first US Food and Drug …

BACKGROUND Bortezomib, a first‐in‐class proteasome inhibitor, has shown clinical activity
in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT. METHODS …

The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple
myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition …

This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib,
which was recently approved by the US Food and Drug Administration for treatment of …

The cancer drug discovery field has placed much emphasis on the identification of novel
and cancer-specific molecular targets. A rich source of such targets for the design of novel …